Business Development Manager
in health
How a Business Development Manager wins revenue across UK health and life sciences and the honest salary bands behind the offer.
A Business Development Manager owns the commercial growth of a product or service sold into health and life sciences. The job is to create, qualify and convert revenue opportunities while protecting the organisation from the avoidable risks that come with clinical environments, sensitive data and slow committee-led buying. The settings vary a lot: an NHS trust buying a workforce platform, a private hospital group choosing a diagnostics partner, a pharma company selecting a contract research organisation (CRO), a device maker opening a new channel, or a health scale-up landing its first reference customers. The common thread is that a sale here rarely happens on charm and a good demo.
This role exists because health and life sciences products almost never sell themselves. Even an excellent product needs trust, evidence, internal alignment and a clean route through procurement, governance and operational constraints before anyone signs. The Business Development Manager is accountable for turning market potential into signed agreements (and renewals or expansions where relevant) without creating downstream delivery obligations the organisation cannot safely meet.
In most organisations this role sits in the commercial function and is measured on outcomes: pipeline quality, win rates, contract value, time-to-close and the health of strategic relationships. The methods differ by setting, but the ownership is consistent. Bring in the right customers, on the right terms, in a way that keeps delivery, compliance and reputation intact.
How this role differs in health and life sciences
In many tech sectors business development can run on speed: generate demand, iterate the pitch, close quickly and let the product prove value after purchase. Health and life sciences changes that operating model. The stakes are higher, the data is more sensitive, and the cost of a poor-fit customer is rarely just churn. It can be operational disruption, a stalled implementation, a reputational hit, or months of governance work that delivers no revenue.
Buying decisions here also tend to be multi-threaded. A yes usually needs more than one enthusiastic end user. Selling into an NHS trust often means clinical sign-off, operational feasibility, an information governance review against the Data Security and Protection Toolkit, and a procurement route through a framework that stands up to scrutiny. Selling pharma services means understanding how the ABPI Code shapes what can be claimed. Selling into device or diagnostics makers means respecting the quality bar your clients answer to (MHRA oversight, ISO 13485, conformity assessment). CQC ratings and NICE guidance frequently sit in the background as the customer's own pressures.
So business development in this market is less about persuasion in the moment and more about building a credible case, aligning stakeholders and choosing opportunities the product and organisation can genuinely support. Strong operators are conservative in the right places. They know when to slow a deal to avoid hidden obligations, and when to accelerate because conditions are aligned.
Core responsibilities in health and life sciences
Day to day, a Business Development Manager shapes a pipeline the company can actually deliver against. The work is concrete:
- Run discovery that distinguishes a real, budgeted problem from a polite conversation, probing clinical workflows, operational pressures and the constraints that break a standard tech-sales approach.
- Map influence across the full buying group: clinical leads, operational owners, information governance, IT, finance and procurement, rather than leaning on a single champion.
- Anticipate the procurement route early, whether an NHS framework, a direct contract or a partner-led deal, and structure terms that can pass scrutiny.
- Qualify hard, and decline or re-scope opportunities that would create unsafe delivery, unrealistic timelines or commitments the team cannot honour.
- Build the commercial case on outcomes, evaluation plans and credible assumptions, not hype, so the buyer can defend the decision internally.
- Negotiate scope, responsibilities and implementation dependencies so the contract reflects the true cost of delivery and avoids unpaid extra work.
- Align product, clinical, security and delivery teams on what is being promised and why, so deals hand over cleanly rather than landing as a surprise.
- Maintain an honest forecast, surfacing risk early rather than letting late-stage governance or go-live delays distort the numbers.
In smaller companies a Business Development Manager may own the full cycle and partner strategy alongside it. In larger ones the role tends to specialise by segment, region or product line, while still being held to measurable revenue outcomes.
Skills and competencies for health and life sciences
| Core skill | What the sector demands | Why it matters |
|---|---|---|
| Stakeholder judgement | Map influence across clinical, operational, governance and procurement contacts without relying on a single champion | Reduces deals that feel agreed but later collapse in governance or procurement, improving win rate and forecast reliability |
| Discovery discipline | Run detailed conversations about workflows, risk tolerance and constraints, not just feature fit | Prevents mis-selling and avoids implementation failures that damage retention, references and regulatory confidence |
| Commercial ownership | Willingness to say no, re-scope or delay when a customer ask creates unsafe delivery or unrealistic timelines | Protects margin, delivery capacity and reputation, which are slow to rebuild in healthcare markets |
| Evidence-led positioning | Communicate value through outcomes, evaluation plans and credible assumptions | Builds trust in conservative buying environments where proof, auditability and patient impact matter |
| Procurement and framework literacy | Understand how NHS frameworks, purchasing routes and contracting terms shape what can be sold and when | Shortens time-to-close by anticipating blockers and structuring deals that survive scrutiny |
| Regulatory context awareness | Know what your customers answer to: the ABPI Code in pharma selling, MHRA and ISO 13485 for device and diagnostics clients, information governance in the NHS | Lets you pitch credibly and avoid claims or commitments that a compliant buyer cannot accept |
| Risk-aware negotiation | Trade concessions for clarity on scope, responsibilities and implementation dependencies | Avoids free-work commitments and reduces delivery risk while keeping the deal commercially viable |
| Cross-functional leadership | Align product, clinical, security and delivery teams around what is being sold | Creates predictable handovers and reduces internal friction that derails late-stage opportunities |
Salary ranges for Business Development Managers in UK health and life sciences
Pay is driven less by the title and more by what the person owns: deal size, the complexity of the buying environment, how regulated or safety-critical the product context is, and whether the role creates net-new revenue or manages and expands existing accounts. Location still matters, but most variation is explained by scope (territory versus national), seniority (individual contributor versus team leadership) and commercial design (commission-heavy roles versus a higher base for longer cycles).
The bands below sit above the generic UK average for the title (a broad market baseline lands around £37,000 to £49,000) because sector specialists earn a premium. Business Development Managers selling medical devices, diagnostics, pharma services or CRO capability typically command higher base pay, and earnings are usually on-target-earnings (OTE) heavy: commission of 50 percent to 100 percent of base is common in field sales, so the realistic total often runs well above the base figures here. Equity appears more in earlier-stage scale-ups. Car allowance, travel and enhanced benefits are frequent in field-based, wide-territory roles.
| Experience level | Estimated annual base salary | What drives compensation |
|---|---|---|
| Junior | London and South East: £35,000 to £50,000. Rest of UK: £30,000 to £45,000 | Closer to an SDR and BD hybrid, smaller deal ownership, tighter enablement and less autonomy on pricing and terms |
| Mid-level | London and South East: £50,000 to £70,000. Rest of UK: £45,000 to £65,000 | Ownership of a defined segment or patch, clearer quota, stronger expectation of self-sourced pipeline and independent deal management |
| Senior | London and South East: £70,000 to £90,000. Rest of UK: £60,000 to £85,000 | Larger contracts, more complex stakeholders, higher expectation to handle governance and procurement, and real influence on commercial strategy |
| Lead | London and South East: £85,000 to £110,000. Rest of UK: £75,000 to £100,000 | Portfolio-level ownership, strategic partnerships, mentoring other sellers and accountability for deal quality and forecasting rather than just personal closes |
| Head or Director | London and South East: £105,000 to £150,000. Rest of UK: £95,000 to £140,000 | Function leadership, revenue strategy, pricing and packaging influence, executive relationships and accountability for team performance and revenue predictability |
Sources: Reed, Prospects and the National Careers Service for the generic UK baseline, plus sector-specific postings and salary guidance from Indeed, Zenopa, Stirling QR and Carter Murray for the medical devices, pharma, CRO and senior bands. Treat these as a guide; real offers move with employer, setting and specialism.
Career pathways
Many Business Development Managers enter from adjacent commercial roles: sales development, account management, healthcare or life-sciences consulting, or supplier-side roles that already required working through clinical stakeholders and procurement. Others move across from non-healthcare B2B sales, and they tend to succeed faster when they treat health and life sciences as a domain to learn deeply rather than a vertical to pitch into.
Progression is usually earned through broader ownership: moving from supporting or sharing deals to independently owning complex opportunities, then to shaping commercial strategy across a segment, and eventually to leading a multi-person motion or a function. The most credible signal of readiness is not tenure. It is whether someone can consistently bring in well-scoped deals that deliver value, protect the organisation's delivery capacity and create referenceable outcomes that compound future growth.
FAQ
How do I prove I can sell into health and life sciences if I have not done it before?
Show that you can run rigorous discovery, manage long buying cycles and hold a multi-stakeholder decision together without losing momentum. Be ready to explain how you have handled risk, governed expectations and protected delivery teams from over-promising. Hiring managers usually prefer strong commercial judgement over a sprinkling of healthcare buzzwords.
Will I be expected to do everything from lead generation to closing?
It depends on company stage and team design. In smaller scale-ups, Business Development Managers often self-source heavily and own the full cycle. In larger teams you may inherit inbound demand or work alongside SDRs and specialists. Ask what share of pipeline is expected to be self-generated, and how much implementation capacity exists, because that caps what can responsibly be sold.
What does success look like beyond hitting quota?
Most teams here care about deal quality as much as deal volume: contracts that pass governance, deliver safely and become reference sites. Expect to be judged on forecast accuracy, stakeholder mapping and how cleanly deals hand over to delivery. If your package is heavily commission-based, clarify how longer procurement cycles and delayed go-lives affect when you actually get paid.
Find your next role
Ready to own commercial growth in health and life sciences? Search Business Development Manager roles on Meeveem and filter for the setting, commercial scope and level of autonomy you want, whether that is an NHS-facing platform, a pharma or CRO partner, a device maker or an early-stage scale-up.